(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a session focusing on rare genitourinary cancers. Dr. Angelika Terbuch discussed current controversies in testis cancer, focusing on the following topics:
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a session focusing on rare genitourinary cancers. Professor Andrea Necchi provided updates on the treatment of penile cancer.
(UroToday.com) The 2024 ESMO annual meeting included a session on testicular cancer, featuring a presentation by Dr. Axel Heidenreich discussing the 3 year update of the prospective COTRIMS trial. Both radiation or chemotherapy represent the standard treatment in clinical stage IIA/B seminoma. Despite high cure rates, both modalities are associated with significant long-term toxicities. The COTRIMS trial evaluated the oncological and functional efficacy of primary retroperitoneal lymphadenectomy (RPLND) without adjuvant chemotherapy in clinical stage IIA/B seminomas.
(UroToday.com) The 2024 ESMO annual meeting included a session on testicular cancer, featuring a presentation by Dr. Deep Chakrabarti discussing the Late CT study assessing the utility of CT scans in the long-term follow-up of metastatic non-seminomatous germ cell tumors (NSGCT). Most patients with metastatic NSGCT are cured by platinum-based chemotherapy.
